Global Human Rabies Immunoglobulin (IM) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Rabies Immunoglobulin (IM) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
Human Rabies Immunoglobulin (IM) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Rabies Immunoglobulin (IM) market is projected to reach US$ 606.3 million in 2034, increasing from US$ 396 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2034. Demand from Category II Exposure and Category III Exposure are the major drivers for the industry.
Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.
In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Rabies Immunoglobulin (IM) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS
Segment by Type
ERIG
HRIG
Category II Exposure
Category III Exposure
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Human Rabies Immunoglobulin (IM) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Rabies Immunoglobulin (IM), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Rabies Immunoglobulin (IM) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Human Rabies Immunoglobulin (IM) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Rabies Immunoglobulin (IM) introduction, etc. Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Human Rabies Immunoglobulin (IM) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
Human Rabies Immunoglobulin (IM) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Rabies Immunoglobulin (IM) market is projected to reach US$ 606.3 million in 2034, increasing from US$ 396 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2034. Demand from Category II Exposure and Category III Exposure are the major drivers for the industry.
Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.
In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Rabies Immunoglobulin (IM) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS
Segment by Type
ERIG
HRIG
Segment by Application
Category II Exposure
Category III Exposure
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Human Rabies Immunoglobulin (IM) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Rabies Immunoglobulin (IM), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Rabies Immunoglobulin (IM) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Human Rabies Immunoglobulin (IM) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Rabies Immunoglobulin (IM) introduction, etc. Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Human Rabies Immunoglobulin (IM) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices